MS
MCID: MLT077
MIFTS: 78

Multiple Sclerosis, Disease Progression, Modifier of (MS) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Ear diseases

Aliases & Classifications for Multiple Sclerosis, Disease Progression, Modifier of

Aliases & Descriptions for Multiple Sclerosis, Disease Progression, Modifier of:

Name: Multiple Sclerosis, Disease Progression, Modifier of 54 29 13 38
Multiple Sclerosis 38 12 50 24 25 51 66 52 41 42 14 69
Ms 50 24 25 66
Light Fixation Seizure Syndrome 69
Generalized Multiple Sclerosis 12
Disseminated Sclerosis 25
Multiple Sclerosis 1 54
Insular Sclerosis 12
M Syndrome 52

Characteristics:

HPO:

32
multiple sclerosis, disease progression, modifier of:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 54 126200
Disease Ontology 12 DOID:2377
ICD10 33 G35 H81.0
ICD9CM 35 340
MeSH 42 D009103
NCIt 47 C3243
MedGen 40 C1868685
UMLS 69 C0026769

Summaries for Multiple Sclerosis, Disease Progression, Modifier of

NIH Rare Diseases : 50 multiple sclerosis (ms) is a degenerative disorder that affects the central nervous system, specifically the brain and the spinal cord. the disorder is characterized by destruction of the myelin, the fatty tissue that surrounds and protects the nerve fibers and promotes the transmission of nerve impulses, and damage to nerve cells. the symptoms vary widely from person to person, and may include sensory disturbances in the limbs, problems with muscle control, tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness, difficulty walking, poor bladder control, and vision problems. most patients have periods during which they have symptoms (clinical attacks). the clinical attacks are typically followed by periods without any symptoms (remission). after several years, the symptoms worsen continuously. multiple sclerosis is considered an autoimmune disorder but the exact cause is unknown. risk factors for developing multiple sclerosis include genetic factors like changes in the hla-drb1 gene and in the il7r gene and environmental factors, such as exposure to the epstein-barr virus, low levels of vitamin d, and smoking. the goal of treatment of ms is to decrease attacks and the inflammation within the central nervous system. last updated: 11/21/2015

MalaCards based summary : Multiple Sclerosis, Disease Progression, Modifier of, also known as multiple sclerosis, is related to hepatitis and rheumatoid arthritis, and has symptoms including muscle weakness, diplopia and emotional lability. An important gene associated with Multiple Sclerosis, Disease Progression, Modifier of is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs 4-Aminopyridine and Glatiramer Acetate have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Disease Ontology : 12 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

Genetics Home Reference : 25 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system.

MedlinePlus : 41 multiple sclerosis (ms) is a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath, the material that surrounds and protects your nerve cells. this damage slows down or blocks messages between your brain and your body, leading to the symptoms of ms. they can include visual disturbances muscle weakness trouble with coordination and balance sensations such as numbness, prickling, or "pins and needles" thinking and memory problems no one knows what causes ms. it may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. multiple sclerosis affects women more than men. it often begins between the ages of 20 and 40. usually, the disease is mild, but some people lose the ability to write, speak, or walk. there is no single test for ms. doctors use a medical history, physical exam, neurological exam, mri, and other tests to diagnose it. there is no cure for ms, but medicines may slow it down and help control symptoms. physical and occupational therapy may also help. nih: national institute of neurological disorders and stroke

NINDS : 51 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus.

UniProtKB/Swiss-Prot : 66 Multiple sclerosis: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

Description from OMIM: 126200

Related Diseases for Multiple Sclerosis, Disease Progression, Modifier of

Diseases related to Multiple Sclerosis, Disease Progression, Modifier of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 490)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.5 HLA-DRB1 IFNG IL10 TNF
2 rheumatoid arthritis 30.4 HLA-DQB1 HLA-DRB1 IFNG IL10 IL17A IL4
3 cryptococcosis 30.0 HLA-DQB1 HLA-DRB1 IL10 IL17A TNF
4 niemann-pick disease 29.8 AQP4 HLA-DRB1 IL17A MBP MOG
5 tuberculosis 29.7 IFNB1 IL10 IL17A IL4 TNF
6 status epilepticus 29.7 AQP4 IFNG IL4 MAG MBP MOG
7 relapsing-remitting multiple sclerosis 12.3
8 secondary progressive multiple sclerosis 12.2
9 primary progressive multiple sclerosis 12.2
10 tumefactive multiple sclerosis 12.2
11 multiple sclerosis 3 12.2
12 progressive relapsing multiple sclerosis 12.2
13 multiple sclerosis 5 12.1
14 pediatric multiple sclerosis 12.0
15 alström syndrome 12.0
16 charlie m syndrome 11.9
17 marburg acute multiple sclerosis 11.9
18 multiple sclerosis 4 11.8
19 multiple sclerosis 2 11.8
20 multiple sclerosis-ichthyosis-factor viii deficiency syndrome 11.8
21 leukodystrophy, adult-onset, autosomal dominant 11.5
22 trigeminal neuralgia 11.3
23 optic neuritis 11.3
24 neuromyelitis optica 11.2
25 foot drop 11.2
26 pars planitis 11.2
27 spasticity 11.2
28 3-m syndrome 1 11.1
29 acute disseminated encephalomyelitis 11.1
30 progressive multifocal leukoencephalopathy 11.1
31 tremor 11.1
32 intermediate uveitis 11.0
33 cadasil 11.0
34 dysphagia 11.0
35 retinal vasculitis 11.0
36 pseudobulbar affect 11.0
37 stiff-person syndrome 11.0
38 glossopharyngeal neuralgia 11.0
39 hypersomnia 11.0
40 myoclonus 11.0
41 rickets 11.0
42 locked-in syndrome 11.0
43 hypertonia 11.0
44 myelinoclastic diffuse sclerosis 11.0
45 optic nerve disease 11.0
46 postinfectious encephalomyelitis 11.0
47 3-m syndrome 3 10.9
48 3-m syndrome 2 10.9
49 cd40 ligand deficiency 10.9
50 central pain syndrome 10.8

Comorbidity relations with Multiple Sclerosis, Disease Progression, Modifier of via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis, Disease Progression, Modifier of:



Diseases related to Multiple Sclerosis, Disease Progression, Modifier of

Symptoms & Phenotypes for Multiple Sclerosis, Disease Progression, Modifier of

Symptoms by clinical synopsis from OMIM:

126200

Clinical features from OMIM:

126200

Human phenotypes related to Multiple Sclerosis, Disease Progression, Modifier of:

32 (show all 10)
id Description HPO Frequency HPO Source Accession
1 muscle weakness 32 HP:0001324
2 diplopia 32 HP:0000651
3 emotional lability 32 HP:0000712
4 depression 32 HP:0000716
5 spasticity 32 HP:0001257
6 paresthesia 32 HP:0003401
7 incoordination 32 HP:0002311
8 urinary incontinence 32 HP:0000020
9 urinary hesitancy 32 HP:0000019
10 cns demyelination 32 HP:0007305

UMLS symptoms related to Multiple Sclerosis, Disease Progression, Modifier of:


back pain, headache, hemiplegia, muscle cramp, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Multiple Sclerosis, Disease Progression, Modifier of according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 PDCD1 TNF HLA-DQB1 IL10 IL17A MX1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 TNF CD40 HLA-DQB1 IL10 IL17A MX1

MGI Mouse Phenotypes related to Multiple Sclerosis, Disease Progression, Modifier of:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 AQP4 CD40 CXCR3 HLA-DQB1 IFNB1 IFNG
2 immune system MP:0005387 10.44 MAG MBP MOG NR1H3 PDCD1 PLP1
3 homeostasis/metabolism MP:0005376 10.43 AQP4 CD40 CNR1 CXCR3 HLA-DQB1 IFNB1
4 cellular MP:0005384 10.35 TNF CNR1 CXCR3 HLA-DQB1 IFNG IL10
5 growth/size/body region MP:0005378 10.33 AQP4 CNR1 HLA-DQB1 IFNG IL10 IL17A
6 behavior/neurological MP:0005386 10.32 AQP4 CNR1 HLA-DQB1 IFNG IL10 MAG
7 nervous system MP:0003631 10.31 IFNG IL10 IL4 MAG MBP MOG
8 mortality/aging MP:0010768 10.29 AQP4 CNR1 CXCR3 HLA-DQB1 IFNG IL10
9 endocrine/exocrine gland MP:0005379 10.26 IFNG IL10 IL17A IL4 NR1H3 PDCD1
10 digestive/alimentary MP:0005381 10.17 AQP4 CNR1 HLA-DQB1 IFNG IL10 IL17A
11 normal MP:0002873 10.07 CD40 CNR1 CXCR3 HLA-DQB1 IFNB1 IFNG
12 muscle MP:0005369 10.06 NR1H3 PDCD1 PLP1 TNF HLA-DQB1 IFNG
13 liver/biliary system MP:0005370 10.04 HLA-DQB1 IFNG IL10 IL4 NR1H3 PDCD1
14 no phenotypic analysis MP:0003012 10.01 AQP4 CNR1 IFNB1 IFNG IL10 IL17A
15 renal/urinary system MP:0005367 9.92 AQP4 CD40 CXCR3 HLA-DQB1 IFNG IL17A
16 reproductive system MP:0005389 9.91 HLA-DQB1 IFNG IL10 IL4 MBP NR1H3
17 respiratory system MP:0005388 9.81 HLA-DQB1 IFNG IL10 IL17A IL4 PDCD1
18 skeleton MP:0005390 9.65 CD40 CNR1 IFNB1 IFNG IL10 IL17A
19 vision/eye MP:0005391 9.28 AQP4 IFNG IL10 IL4 MBP MOG

Drugs & Therapeutics for Multiple Sclerosis, Disease Progression, Modifier of

Drugs for Multiple Sclerosis, Disease Progression, Modifier of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 669)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Phase 1 504-24-5 1727
2
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
4
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 189261-10-7
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Ziconotide Approved Phase 4 107452-89-1 447451
9
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 24280-93-1 446541
13
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
14
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
15
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
16
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145258-61-3 6438354
17
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2 65271-80-9 4212
18
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
19
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
20
Ethanol Approved Phase 4,Phase 3,Early Phase 1 64-17-5 702
21
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
22
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
23
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
24
Menthol Approved Phase 4,Phase 1,Early Phase 1 2216-51-5 16666
25
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216503-57-0
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3 112111-43-0
28
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3 68693-11-8 4236
29
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
30
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
31
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
32
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
33
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
34 Piracetam Approved Phase 4 7491-74-9
35
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
36
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
37
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
38
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
39
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
40
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
42
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
43
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
44
Glycerol Approved, Experimental Phase 4 56-81-5 753
45 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
46
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
47
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
48
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
49
Cetirizine Approved Phase 4 83881-51-0 2678
50
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 1832)
id Name Status NCT ID Phase
1 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
2 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4
3 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4
4 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4
5 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
6 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4
7 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
8 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4
9 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4
10 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
11 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
12 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
13 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
14 Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy Unknown status NCT01992562 Phase 4
15 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
16 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4
17 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4
18 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4
19 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4
20 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4
21 A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Completed NCT01216072 Phase 4
22 Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients Completed NCT01658384 Phase 4
23 Levetiracetam in Central Pain in Multiple Sclerosis(MS) Completed NCT00423527 Phase 4
24 Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis Completed NCT00468182 Phase 4
25 Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis Completed NCT00963833 Phase 4
26 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
27 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
28 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4
29 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4
30 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4
31 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4
32 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4
33 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4
34 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
35 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
36 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Completed NCT01480076 Phase 4
37 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4
38 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4
39 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4
40 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4
41 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4
42 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis Completed NCT00381264 Phase 4
43 A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis Completed NCT01356940 Phase 4
44 Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients Completed NCT00262314 Phase 4
45 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
46 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4
47 EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Completed NCT00146068 Phase 4
48 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4
49 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4
50 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4

Search NIH Clinical Center for Multiple Sclerosis, Disease Progression, Modifier of

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Multiple Sclerosis, Disease Progression, Modifier of:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis, Disease Progression, Modifier of:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 21366911 22236384 22277374
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19127447 19603590
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis, Disease Progression, Modifier of

Genetic tests related to Multiple Sclerosis, Disease Progression, Modifier of:

id Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 29
2 Multiple Sclerosis 24

Anatomical Context for Multiple Sclerosis, Disease Progression, Modifier of

MalaCards organs/tissues related to Multiple Sclerosis, Disease Progression, Modifier of:

39
Spinal Cord, Brain, Bone, Testes, Monocytes, Bone Marrow, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis, Disease Progression, Modifier of:
id Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis, Disease Progression, Modifier of